PRODUCT INFORMATION



Amyloid- β (17-40) Peptide (human) (trifluoroacetate salt)

Item No. 27414

Formal Name:	L-leucyl-L-valyl-L-phenylalanyl-L- phenylalanyl-L-alanyl-L-α-glutamyl-L-α- aspartyl-L-valylglycyl-L-seryl-L-asparaginyl-	
	L-lysylglycyl-L-alanyl-L-isoleucyl-L-L-	
	isoleucylglycyl-L-leucyl-L-methionyl-L-	H-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-
	valylglycylglycyl-L-valyl-L-valine	Asn—Lys—Gly—Ala—IIe—IIe—Gly—Leu—Met—Val—
Synonym:	Αβ (17-40)	Glv-Glv-Val-Val-OH
MF:	C ₁₁₀ H ₁₇₈ N ₂₆ O ₃₁ S • XCF ₃ COOH	-, -, -, -, -, -, -, -, -, -, -, -, -, -
FW:	2,392.8	• XCF ₃ COOH
Purity:	≥95%	
Supplied as:	A solid	
Storage:	-20°C	
Stability:	≥4 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Amyloid- β (A β) (17-40) peptide (human) (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the A β (17-40) peptide (human) (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. A β (17-40) peptide (human) (trifluoroacetate salt) is soluble in the organic solvent formic acid at a concentration of approximately 1 mg/ml.

Description

A β (17-40) is a 24-residue fragment of the A β protein that is formed via post-translational processing of amyloid precursor protein (APP) by α - and γ -secretases.¹ In vitro, A β (17-40) polymerizes into lattice-like structures that do not bind thioflavin T. It inhibits interactions between fibrinogen and biotinylated Aβ (1-42) (Item No. 27410) as well as between cholesterol and apolipoprotein E (ApoE) with IC₅₀ values of 13.4 and $25 \,\mu$ M, respectively ^{2,3} A β (17-40) increases the rate of A β (1-40) (Item No. 21617) aggregation in vitro when used at an equimolar concentration.⁴ A β (17-40) (25 μ M) induces cell death in cultured rat hippocampal neurons.5

References

- 1. Näslund, J., Jensen, M., Tjernberg, L.O., et al. The metabolic pathway generating p3, an A β -peptide fragment, is probably non-amyloidogenic. Biochem. Biophys. Res. Commun. 204(2), 780-787 (1994).
- Zamolodchikov, D., Berk-Rauch, H.E., Oren, D.A., et al. Biochemical and structural analysis of the 2. interaction between β-amyloid and fibrinogen. Blood 128(8), 1144-1151 (2016).
- Yao, Z.X. and Papadopoulos, V. Function of β -amyloid in cholesterol transport: A lead to neurotoxicity. 3. FASEB J. 16(12), 1677-1679 (2002).
- 4. Liu, R., McAllister, C., Lyubchenko, Y., et al. Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation. J. Neurosci. Res. 75(2), 162-171 (2004).
- 5. Pike, C.J., Overman, M.J., and Cotman, C.W. Amino-terminal deletions enhance aggregation of β -amyloid peptides in vitro. J. Biol. Chem. 270(41), 23895-23898 (1995).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/22/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM